| Followers | 1 |
| Posts | 68 |
| Boards Moderated | 0 |
| Alias Born | 02/23/2021 |
Saturday, October 18, 2025 4:24:25 PM
I respectfully disagree here. The company has already indicated (per Jesse) that they are likely to look for a buyout in 2026. If Blarcamesine only receives a CMA, then the buyout value will be materially discounted compared to a standard MA. In a buyout situation, there is no "delay the realization of max value". I think we can all agree that a CMA introduces additional risks to the acquiring party compared to a standard MA.
Now, if Anavex stays independent then this is largely irrelevant in the long run, but you would also need to recognize that a CMA affects Anavex's negotiation leverage in partnership discussions, since the partner will need to invest a material amount of time and money and any risk that this investment will evaporate is an argument against a very lucrative deal for Anavex.
In short - I am discouraged by this discussion of a CMA. I understand that as Anavex applied for a full MA, it should either receive or be denied a full MA so I don't quite understand where this CMA idea is coming from beyond MayoMobile. I would also believe that any such movement is material discussion that should be released by the company and, if not, I agree with Hoskuld that this is a legitimate basis for a lawsuit against the firm and a strike against management's judgement.
I see that MayoMobile says a CMA is a logical conclusion but I don't see how he arrives at this conclusion. I would like it if he can elaborate his logic here with citations to the relevant places in EMA's procedure that allows this.
Now, if Anavex stays independent then this is largely irrelevant in the long run, but you would also need to recognize that a CMA affects Anavex's negotiation leverage in partnership discussions, since the partner will need to invest a material amount of time and money and any risk that this investment will evaporate is an argument against a very lucrative deal for Anavex.
In short - I am discouraged by this discussion of a CMA. I understand that as Anavex applied for a full MA, it should either receive or be denied a full MA so I don't quite understand where this CMA idea is coming from beyond MayoMobile. I would also believe that any such movement is material discussion that should be released by the company and, if not, I agree with Hoskuld that this is a legitimate basis for a lawsuit against the firm and a strike against management's judgement.
I see that MayoMobile says a CMA is a logical conclusion but I don't see how he arrives at this conclusion. I would like it if he can elaborate his logic here with citations to the relevant places in EMA's procedure that allows this.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
